|
|
|
|
|
|
| Paper offers innovative approaches to bringing drugs to market faster and reducing development costs |
Raleigh, NC, June 19, 2013 - (ACN Newswire) - INC Research, LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process(R) for delivering reliable results, today announced it has released a new white paper titled, "Clinical Process Innovations for New Drug Development: Aligning Clinical Trials with Development Needs." INC Research's paper explores the challenges biopharms face in bringing new drugs to market and describes the latest clinical innovations that are improving this process.
Biopharms are trapped between mounting pressure to reduce development costs and the need to ensure better outcomes from clinical trials. Generics, lower approval rates, and global testing requirements have increased drug development costs. Yet, outcomes have remained uncertain in terms of both regulatory approval and market acceptance, and large payers continue to exert downward pressure on prices. However, recent guidance from the Federal Drug Administration (FDA) and other regulatory bodies has paved the way for a more risk-based approach to collecting and verifying trial data. The pharmaceutical industry has also begun to embrace data analytics and reporting. Together these factors are creating an opportunity to significantly reduce research and development costs while providing more predictable outcomes.
"Despite continued R&D spending, approvals on compounds have declined or remained flat. The spending problem is compounded by a slow drug development process and a challenging regulatory environment," said INC Research CEO Jamie Macdonald. "INC Research has been helping biopharms overcome these obstacles by leveraging recent regulatory changes around the use of new data monitoring techniques and advanced technology platforms to improve visibility into outcomes. These innovations, combined with our data-driven Trusted Process(R) methodology and extensive therapeutic expertise, are enabling biopharms to make better use of their drug development capital."
INC's white paper discusses today's trends impacting clinical drug trials, evolving challenges of conducting more efficient trials, and how best to implement clinical process innovation within three key phases: planning, engineering, execution and control.
As a leading CRO providing the full range of Phase I to IV clinical development services on a worldwide scale, INC Research helps biopharms achieve greater efficiency in bringing new drugs to market through a proven methodology that supports consistent quality, reduced trial variability and complete transparency for every phase of a development program. Using advanced data monitoring and management systems, INC Research is able to provide a real-time status on all projects and test sites. This active monitoring allows for the early detection and response to emerging risks providing sponsors a high level of visibility and predictability across their clinical trial programs.
To download a copy of "Clinical Process Innovations for New Drug Development: Aligning Clinical Trials with Development Needs," visit http://bit.ly/17kM3Dd .
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process(R) methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.
Contact:
Lori Dorer, Media +1-513-345-1685
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
Topic: Research / Industry Report
Source: INC Research, LLC
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
